Vericel Corporation (NASDAQ:VCEL) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas lowered its stake in Vericel Corporation (NASDAQ:VCEL) by 8.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 13,282 shares of the biotechnology company’s stock after selling 1,246 shares during the quarter. Teacher Retirement System of Texas’ holdings in Vericel were worth $593,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VCEL. Charles Schwab Investment Management Inc. grew its position in shares of Vericel by 4.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 451,464 shares of the biotechnology company’s stock valued at $24,790,000 after purchasing an additional 17,258 shares during the period. Proficio Capital Partners LLC purchased a new stake in Vericel during the 4th quarter worth approximately $956,000. Amundi increased its stake in Vericel by 184.6% during the 4th quarter. Amundi now owns 24,568 shares of the biotechnology company’s stock worth $1,463,000 after buying an additional 15,936 shares in the last quarter. Avantax Advisory Services Inc. raised its holdings in shares of Vericel by 1.7% during the fourth quarter. Avantax Advisory Services Inc. now owns 13,803 shares of the biotechnology company’s stock valued at $758,000 after acquiring an additional 234 shares during the last quarter. Finally, Swiss National Bank boosted its stake in shares of Vericel by 6.7% in the fourth quarter. Swiss National Bank now owns 96,500 shares of the biotechnology company’s stock worth $5,299,000 after acquiring an additional 6,100 shares during the last quarter.

Vericel Stock Performance

Vericel stock opened at $37.10 on Wednesday. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 1,237.08 and a beta of 1.32. Vericel Corporation has a 1 year low of $36.94 and a 1 year high of $63.00. The company’s 50 day simple moving average is $41.85 and its 200-day simple moving average is $47.23.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.14). Vericel had a return on equity of 1.09% and a net margin of 1.25%. The business had revenue of $52.60 million for the quarter, compared to analysts’ expectations of $53.86 million. During the same period in the previous year, the company earned ($0.08) earnings per share. Vericel’s quarterly revenue was up 2.6% on a year-over-year basis. Equities analysts expect that Vericel Corporation will post 0.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on VCEL. Stephens restated an “overweight” rating and issued a $67.00 price objective on shares of Vericel in a report on Monday, June 16th. Truist Financial reduced their price objective on Vericel from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. Finally, Wall Street Zen cut Vericel from a “hold” rating to a “sell” rating in a report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.14.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.